Phase I study for dose escalation in limited small cell lung cancer

Phase I study for dose escalation in limited small cell lung cancer - Phase I study for dose escalation in limited small cell lung cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005911

Enrollment

Registered

2011-07-02

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limited small cell lung cancer

Interventions

3DCRT:Radiotherapy Arm 1:48Gy1.5 Gyb.i.d./22d Arm 2:54Gy1/24d Arm 3:60Gy/4wks=26d Arm 4:66Gy32d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologically diagnosed as a limited NSCLC 2) Fresh case 3) ECOG PD 0-1 4) Wtitten informed consent

Exclusion criteria

Exclusion criteria: 1) Uncontrollable DM 2) Collagen disease 3) Concurrent cancer with activity 4) Pregnant 5) Elonging treatment time

Design outcomes

Primary

Measure	Time frame
Acute toxicity G3 or more	—

Countries

Japan

Contacts

Public Contactoffice

Graduate School of Medical Science, Kyoto Prefectural University of Medicine IRB

rinri@koto.kpu-m.ac.jp075-251-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026